Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report)’s share price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.09 and traded as low as $0.07. Nascent Biotech shares last traded at $0.07, with a volume of 103,490 shares traded.
Nascent Biotech Stock Down 21.3 %
The firm has a 50 day moving average price of $0.09 and a two-hundred day moving average price of $0.12.
Nascent Biotech Company Profile
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Featured Articles
- Five stocks we like better than Nascent Biotech
- The Significance of Brokerage Rankings in Stock Selection
- RXO Shares Surge Following New Acquisition Deal
- How to Use the MarketBeat Excel Dividend Calculator
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
